Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23338428 | 0.80 | — | — | |
| SCHEMBL30782079 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2PIK3CD | |
| SCHEMBL26620418 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2PIK3CD | |
| SCHEMBL20148575 | 0.75 | SMN1; SMN2 (0.45) | SMN1; SMN2PIK3CDCYP3A4MAPK1 | |
| SCHEMBL24316024 | 0.73 | PIK3CD (0.41) | SMN1; SMN2PIK3CDCYP3A4MAPK1 | |
| SCHEMBL27010394 | 0.72 | — | — | |
| SCHEMBL24317927 | 0.71 | — | — | |
| SCHEMBL27010279 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2PIK3CD | |
| SCHEMBL27010399 | 0.68 | — | — | |
| SCHEMBL9882851 | 0.67 | SMN1; SMN2 (0.50) | SMN1; SMN2PIK3CDCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | SMN1; SMN2 524/4885PIK3CD 3005/4885CYP3A4 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.